Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATA 3271

Next Previous
Drug Profile

ATA 3271

Alternative Names: Anti-mesothelin allogenic CAR T cell therapy - Atara Biotherapeutics; Anti-mesothelin allogenic chimeric antigen receptor T cell therapy - Atara Biotherapeutics; ATA-3271

Latest Information Update: 27 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Atara Biotherapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Mesothelioma; Solid tumours

Most Recent Events

  • 19 May 2022 Atara Biotherapeutics receives notification of Bayer’s intention to end the licensing agreement for ATA 3271 worldwide
  • 10 Jan 2022 Atara Biotherapeutics announces intention to submit IND to US FDA for Mesothelioma in Q4 2022
  • 04 May 2021 Atara Biotherapeutics plans to file an IND application with the US FDA for Solid tumours in Q2/Q3 of 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top